RGD-PET-CT in Cancer Angiogenesis

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

18F-RGD-PET-CT and perfusion CT scans on 3 occasions

"Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions"

Trial Locations (1)

OX3 7LJ

Department of Radiology, Oxford University Hospitals NHS Trust, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GE Healthcare

INDUSTRY

collaborator

University of Oxford

OTHER

lead

Oxford University Hospitals NHS Trust

OTHER